Cargando…

Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?

The world faces an exceptional new public health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequently termed the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Although the clinical symptoms mostly have been characterized, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Romero, Alejandro, Ramos, Eva, López-Muñoz, Francisco, Gil-Martín, Emilio, Escames, Germaine, Reiter, Russel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415199/
https://www.ncbi.nlm.nih.gov/pubmed/32772307
http://dx.doi.org/10.1007/s10571-020-00938-8
_version_ 1783569122541436928
author Romero, Alejandro
Ramos, Eva
López-Muñoz, Francisco
Gil-Martín, Emilio
Escames, Germaine
Reiter, Russel J.
author_facet Romero, Alejandro
Ramos, Eva
López-Muñoz, Francisco
Gil-Martín, Emilio
Escames, Germaine
Reiter, Russel J.
author_sort Romero, Alejandro
collection PubMed
description The world faces an exceptional new public health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequently termed the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Although the clinical symptoms mostly have been characterized, the scientific community still doesn´t know how SARS-CoV-2 successfully reaches and spreads throughout the central nervous system (CNS) inducing brain damage. The recent detection of SARS-CoV-2 in the cerebrospinal fluid (CSF) and in frontal lobe sections from postmortem examination has confirmed the presence of the virus in neural tissue. This finding reveals a new direction in the search for a neurotherapeutic strategy in the COVID-19 patients with underlying diseases. Here, we discuss the COVID-19 outbreak in a neuroinvasiveness context and suggest the therapeutic use of high doses of melatonin, which may favorably modulate the immune response and neuroinflammation caused by SARS-CoV-2. However, clinical trials elucidating the efficacy of melatonin in the prevention and clinical management in the COVID-19 patients should be actively encouraged.
format Online
Article
Text
id pubmed-7415199
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-74151992020-08-10 Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin? Romero, Alejandro Ramos, Eva López-Muñoz, Francisco Gil-Martín, Emilio Escames, Germaine Reiter, Russel J. Cell Mol Neurobiol Review Paper The world faces an exceptional new public health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequently termed the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Although the clinical symptoms mostly have been characterized, the scientific community still doesn´t know how SARS-CoV-2 successfully reaches and spreads throughout the central nervous system (CNS) inducing brain damage. The recent detection of SARS-CoV-2 in the cerebrospinal fluid (CSF) and in frontal lobe sections from postmortem examination has confirmed the presence of the virus in neural tissue. This finding reveals a new direction in the search for a neurotherapeutic strategy in the COVID-19 patients with underlying diseases. Here, we discuss the COVID-19 outbreak in a neuroinvasiveness context and suggest the therapeutic use of high doses of melatonin, which may favorably modulate the immune response and neuroinflammation caused by SARS-CoV-2. However, clinical trials elucidating the efficacy of melatonin in the prevention and clinical management in the COVID-19 patients should be actively encouraged. Springer US 2020-08-09 2022 /pmc/articles/PMC7415199/ /pubmed/32772307 http://dx.doi.org/10.1007/s10571-020-00938-8 Text en © Springer Science+Business Media, LLC, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Paper
Romero, Alejandro
Ramos, Eva
López-Muñoz, Francisco
Gil-Martín, Emilio
Escames, Germaine
Reiter, Russel J.
Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
title Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
title_full Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
title_fullStr Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
title_full_unstemmed Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
title_short Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
title_sort coronavirus disease 2019 (covid-19) and its neuroinvasive capacity: is it time for melatonin?
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415199/
https://www.ncbi.nlm.nih.gov/pubmed/32772307
http://dx.doi.org/10.1007/s10571-020-00938-8
work_keys_str_mv AT romeroalejandro coronavirusdisease2019covid19anditsneuroinvasivecapacityisittimeformelatonin
AT ramoseva coronavirusdisease2019covid19anditsneuroinvasivecapacityisittimeformelatonin
AT lopezmunozfrancisco coronavirusdisease2019covid19anditsneuroinvasivecapacityisittimeformelatonin
AT gilmartinemilio coronavirusdisease2019covid19anditsneuroinvasivecapacityisittimeformelatonin
AT escamesgermaine coronavirusdisease2019covid19anditsneuroinvasivecapacityisittimeformelatonin
AT reiterrusselj coronavirusdisease2019covid19anditsneuroinvasivecapacityisittimeformelatonin